Abbott Laboratories (ABT) said a new showed that patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of therapy with Niaspan plus a statin.
In a pre-specified secondary endpoint of the ARBITER 6 - HALTS study, treatment with Niaspan plus statin also resulted in significantly fewer major adverse cardiac events, as compared to ezetimibe plus a statin.
The ARBITER 6 - HALTS study explored treatment approaches in patients at high cardiovascular risk already taking statins to control bad LDL cholesterol.
The company noted that the study was stopped early after a pre-specified interim analysis was conducted on 208 patients who had completed treatment and had undergone final ultrasound imaging of the carotid artery to measure the impact of treatment on atherosclerosis.
For comments and feedback: editorial@rttnews.com